Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PDEX NASDAQ:PROF NYSE:RBOT NASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePDEXPro-Dex$33.81+3.6%$44.87$23.68▼$70.26$110.22M-0.0446,051 shs44,181 shsPROFProfound Medical$4.04-1.2%$5.11$3.76▼$9.17$121.69M0.5577,253 shs55,565 shsRBOTVicarious Surgical$5.93+0.6%$8.05$5.00▼$19.00$35.14M1.430,572 shs12,642 shsRCELAvita Medical$6.25-7.5%$5.13$3.60▼$14.16$166.37M1.58390,773 shs968,484 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePDEXPro-Dex-1.36%-8.29%-23.66%-23.48%+22.22%PROFProfound Medical+1.24%-0.49%-3.76%-39.76%-47.02%RBOTVicarious Surgical-1.27%-6.85%-13.97%-23.93%+0.52%RCELAvita Medical+48.25%+60.57%+20.07%+29.75%-34.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePDEXPro-Dex$33.81+3.6%$44.87$23.68▼$70.26$110.22M-0.0446,051 shs44,181 shsPROFProfound Medical$4.04-1.2%$5.11$3.76▼$9.17$121.69M0.5577,253 shs55,565 shsRBOTVicarious Surgical$5.93+0.6%$8.05$5.00▼$19.00$35.14M1.430,572 shs12,642 shsRCELAvita Medical$6.25-7.5%$5.13$3.60▼$14.16$166.37M1.58390,773 shs968,484 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePDEXPro-Dex-1.36%-8.29%-23.66%-23.48%+22.22%PROFProfound Medical+1.24%-0.49%-3.76%-39.76%-47.02%RBOTVicarious Surgical-1.27%-6.85%-13.97%-23.93%+0.52%RCELAvita Medical+48.25%+60.57%+20.07%+29.75%-34.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePDEXPro-Dex 3.00Buy$56.0064.61% UpsidePROFProfound Medical 3.00Buy$11.00170.34% UpsideRBOTVicarious Surgical 2.00Hold$7.0017.85% UpsideRCELAvita Medical 2.40Hold$11.6080.26% UpsideCurrent Analyst Ratings BreakdownLatest RBOT, PDEX, PROF, and RCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.009/5/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $14.008/13/2025RBOTVicarious SurgicalPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$8.50 ➝ $7.008/11/2025RCELAvita MedicalLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $8.008/8/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$19.00 ➝ $18.008/8/2025RCELAvita MedicalBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$3.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPDEXPro-Dex$66.59M1.67$3.22 per share10.55$11.23 per share3.03PROFProfound Medical$11.84M10.35N/AN/A$2.01 per share2.02RBOTVicarious SurgicalN/AN/AN/AN/A$7.89 per shareN/ARCELAvita Medical$74.88M2.29N/AN/A$0.17 per share37.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePDEXPro-Dex$8.98M$2.7012.7016.51N/A13.48%26.67%14.95%10/30/2025 (Estimated)PROFProfound Medical-$27.82M-$1.46N/AN/AN/A-343.97%-89.74%-73.06%11/6/2025 (Estimated)RBOTVicarious Surgical-$63.22M-$10.09N/AN/AN/AN/A-148.14%-98.07%11/11/2025 (Estimated)RCELAvita Medical-$61.85M-$1.97N/AN/AN/A-68.87%-632.62%-71.52%11/6/2025 (Estimated)Latest RBOT, PDEX, PROF, and RCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/4/2025Q4 2025PDEXPro-Dex$0.47$0.36-$0.11$0.36$17.90 million$17.49 million8/14/2025Q2 2025PROFProfound Medical-$0.43-$0.52-$0.09-$0.52$4.75 million$2.21 million8/12/2025Q2 2025RBOTVicarious Surgical-$2.61-$2.23+$0.38-$2.23N/AN/A8/7/2025Q2 2025RCELAvita Medical-$0.26-$0.38-$0.12-$0.38$34.27 million$18.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPDEXPro-DexN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ARBOTVicarious SurgicalN/AN/AN/AN/AN/ARCELAvita MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPDEXPro-Dex0.253.231.71PROFProfound Medical0.118.537.07RBOTVicarious SurgicalN/A5.115.11RCELAvita Medical9.390.580.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPDEXPro-Dex15.28%PROFProfound Medical47.86%RBOTVicarious Surgical47.27%RCELAvita Medical27.66%Insider OwnershipCompanyInsider OwnershipPDEXPro-Dex47.50%PROFProfound Medical1.52%RBOTVicarious Surgical11.99%RCELAvita Medical2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePDEXPro-Dex1403.26 million1.71 millionNot OptionablePROFProfound Medical15030.12 million29.66 millionOptionableRBOTVicarious Surgical2105.93 million5.22 millionNo DataRCELAvita Medical13026.62 million25.87 millionOptionableRBOT, PDEX, PROF, and RCEL HeadlinesRecent News About These CompaniesAvita Medical's (RCEL) "Buy" Rating Reaffirmed at D. Boral CapitalSeptember 16 at 8:08 AM | marketbeat.comAVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the FirmSeptember 15 at 5:45 PM | globenewswire.comD. Boral Capital Sticks to Their Buy Rating for Avita Medical (RCEL)September 14 at 6:50 PM | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCELSeptember 13 at 10:00 AM | prnewswire.comRCEL Investors Have Opportunity to Join AVITA Medical, Inc. Fraud Investigation with the Schall Law FirmSeptember 11, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCELSeptember 10, 2025 | globenewswire.comAVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law FirmSeptember 9, 2025 | globenewswire.comRCEL Alert: Kirby McInerney LLP Encourages AVITA Medical, Inc. Investors to Inquire about InvestigationSeptember 9, 2025 | businesswire.comAVITA Medical, Inc. (RCEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.comAvita Medical (NASDAQ:RCEL) Given New $14.00 Price Target at D. Boral CapitalSeptember 7, 2025 | americanbankingnews.com71,738 Shares in Avita Medical Inc. $RCEL Purchased by Nuveen LLCSeptember 6, 2025 | marketbeat.comBrokerages Set Avita Medical Inc. (NASDAQ:RCEL) Price Target at $12.40September 6, 2025 | americanbankingnews.comAvita Medical says data shows hospital stay reduction with RCELL SystemSeptember 4, 2025 | msn.comSecurities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmSeptember 4, 2025 | globenewswire.comAvita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 4, 2025 | marketbeat.comAVITA Medical, Inc. (RCEL) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationSeptember 3, 2025 | globenewswire.comSecurities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzSeptember 3, 2025 | globenewswire.comWellington Management Group LLP Acquires Shares of 82,206 Avita Medical Inc. $RCELSeptember 3, 2025 | marketbeat.comAvita Medical (NASDAQ:RCEL) Director Robert Mcnamara Purchases 10,000 SharesAugust 30, 2025 | insidertrades.comAVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law FirmAugust 28, 2025 | globenewswire.comAVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the FirmAugust 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTake Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025Buffett’s Wisdom Could Spell Trouble for Palantir ShortsBy Chris Markoch | August 26, 2025What to Watch for From D-Wave Now That Earnings Are DoneBy Nathan Reiff | September 2, 2025Time to Take Profits on Strategy Stock? 3 Reasons You ShouldBy Gabriel Osorio-Mazilli | September 1, 2025DLocal Stock Soars 43% After Earnings Beat and Raised GuidanceBy Ryan Hasson | August 19, 2025RBOT, PDEX, PROF, and RCEL Company DescriptionsPro-Dex NASDAQ:PDEX$33.81 +1.19 (+3.65%) Closing price 04:00 PM EasternExtended Trading$33.82 +0.00 (+0.01%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Profound Medical NASDAQ:PROF$4.04 -0.05 (-1.22%) Closing price 03:59 PM EasternExtended Trading$4.04 0.00 (-0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.Vicarious Surgical NYSE:RBOT$5.92 +0.04 (+0.59%) Closing price 03:58 PM EasternExtended Trading$5.94 +0.02 (+0.34%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Avita Medical NASDAQ:RCEL$6.25 -0.51 (-7.54%) Closing price 04:00 PM EasternExtended Trading$6.26 +0.00 (+0.08%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
